6th Digital Pharma & Life Sciences Conference 2011

22 February 2011, Wiesbaden, Germany.
For the sixth time Microsoft and its partners will be holding the Digital Pharma & Life Sciences conference. The lecture event and exhibition is aimed at the pharmaceutical, chemical and life sciences industries, showing current projects and innovative technologies that support greater sustainability, cost efficiency and competitiveness in and through IT.

IT has become a critical competitive factor as an instrument for sustainable climate and environmental protection. The framework is set by international initiatives by industries and governments: for example more than 500 investors request global listed companies to report their CO2 relevant business data through the Carbon Disclosure Project (CDP) from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Rotterdam and Basel, the OECD and the regulatory authorities of developed countries are working to create global standards for sustainable risk and chemicals management.

For this reason, the Digital Pharma & Life Sciences conference 2011 is focussing on the topics "Green IT – Green Chemistry". With the focus on "Green in IT", experts will discuss latest developments of Green IT technologies on the basis of recent successful projects in order to make processes more efficient, save resources and energy and thereby reduce costs. These include concepts for IT virtualization in controlling chemical production or cloud computing for pharmaceutical research.

The "Green through IT" presentations will show pioneering Green Chemistry projects that ensure sustainability in production, research and development and overall global supply chains. Leading companies from the chemical, pharmaceutical and life sciences industries demonstrate how they coordinate production and logistics processes better through intelligent technologies, plan forward-looking and therefore design initiatives for more economically measurable sustainability.

The conference takes place on 22nd February 2011 in the Kurhaus Wiesbaden and is aimed at decision makers and experts from the fields of IT and business management, research and development, business development management, product management, production, quality management, sales and controlling.

During the accompanying exhibition, the partners of the Digital Pharma & Life Sciences initiative will show latest IT technologies and reference projects. On the eve of the conference on 21st February 2011, an exclusive dinner will take place with all the speakers, conference participants and partners of the initiative.

Further information for registration, the agenda and logistic details are available at:
http://www.digitalpharma.de

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...